StreetInsider.com News Articles

Form S-4 Indivior Pharmaceuticals

Fri, 28 Aug 2026 16:56:00 -0400

http://archive.fast-edgar.com/20260828/ASBZB22D8222P2Z2222B2MZZPLW9Z2X2XL82

Filed on: August 28, 2026

Form S-4 Indivior Pharmaceuticals

Fri, 28 Aug 2026 16:56:00 -0400

http://archive.fast-edgar.com/20260828/ASBZB22D8222P2Z2222B2MZZPLW9Z2X2XL82

Filed on: August 28, 2026

Form 4 Indivior Pharmaceuticals For: Aug 27 Filed by: Anderson Woodrow D

Thu, 27 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260827/26989705.html

Form 4 Indivior Pharmaceuticals For: Aug 27 Filed by: Anderson Woodrow D

Thu, 27 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260827/26989705.html

Form SCHEDULE 13D/A Indivior Pharmaceuticals Filed by: Oaktree Capital Holdings, LLC

Thu, 13 Aug 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260813/26922911.html

Form SCHEDULE 13D/A Indivior Pharmaceuticals Filed by: Oaktree Capital Holdings, LLC

Thu, 13 Aug 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260813/26922911.html

Form 4 Indivior Pharmaceuticals For: Aug 05 Filed by: Anderson Woodrow D

Wed, 05 Aug 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260805/26875486.html

Form 4 Indivior Pharmaceuticals For: Aug 05 Filed by: Anderson Woodrow D

Wed, 05 Aug 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260805/26875486.html

Indivior (INDV) PT Lowered to $43 at Barclays

Wed, 05 Aug 2026 04:28:48 -0400

Barclays analyst Glen Santangelo lowered the price target on Indivior (NASDAQ: INDV) to $43.00 (from $46.00) while maintaining a Overweight rating.

Form 10-Q Indivior Pharmaceuticals For: Jun 30

Mon, 03 Aug 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260803/26858365.html

Form 10-Q Indivior Pharmaceuticals For: Jun 30

Mon, 03 Aug 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260803/26858365.html

Form 425 Indivior Pharmaceuticals Filed by: Indivior Pharmaceuticals, Inc.

Mon, 03 Aug 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260803/26854533.html

Form 425 Indivior Pharmaceuticals Filed by: Indivior Pharmaceuticals, Inc.

Mon, 03 Aug 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260803/26854533.html

Form 8-K Indivior Pharmaceuticals For: Aug 03

Mon, 03 Aug 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260803/26854528.html

Form 8-K Indivior Pharmaceuticals For: Aug 03

Mon, 03 Aug 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260803/26854528.html

Indivior PLC (INDV) Tops Q2 EPS by 41c ; Offers Guidance

Mon, 03 Aug 2026 07:07:06 -0400

Indivior PLC (NASDAQ: INDV) reported Q2 EPS of $1.15, $0.41 better than the analyst estimate of $0.74. Revenue for the quarter came in at $343 million versus the consensus estimate of $284.9 million.

FY 2026 Outlook:-

Revenue between $1.295 billion to $1.365 billion vs consensus $1.26 billion.

For earnings history and earnings-related data on Indivior PLC (INDV) click here.

Form 425 Indivior Pharmaceuticals Filed by: Indivior Pharmaceuticals, Inc.

Mon, 03 Aug 2026 06:53:00 -0400

si-local-file:///var/storage/secattach/20260803/26853619.html

Form 425 Indivior Pharmaceuticals Filed by: Indivior Pharmaceuticals, Inc.

Mon, 03 Aug 2026 06:53:00 -0400

si-local-file:///var/storage/secattach/20260803/26853619.html

Form 8-K Indivior Pharmaceuticals For: Aug 03

Mon, 03 Aug 2026 06:50:00 -0400

si-local-file:///var/storage/secattach/20260803/26853616.html

Form 8-K Indivior Pharmaceuticals For: Aug 03

Mon, 03 Aug 2026 06:50:00 -0400

si-local-file:///var/storage/secattach/20260803/26853616.html

Form 425 Indivior Pharmaceuticals Filed by: Indivior Pharmaceuticals, Inc.

Mon, 03 Aug 2026 06:43:00 -0400

si-local-file:///var/storage/secattach/20260803/26853566.html

Form 425 Indivior Pharmaceuticals Filed by: Indivior Pharmaceuticals, Inc.

Mon, 03 Aug 2026 06:43:00 -0400

si-local-file:///var/storage/secattach/20260803/26853566.html

Form 8-K Indivior Pharmaceuticals For: Aug 01

Mon, 03 Aug 2026 06:41:00 -0400

si-local-file:///var/storage/secattach/20260803/26853551.html

Form 8-K Indivior Pharmaceuticals For: Aug 01

Mon, 03 Aug 2026 06:41:00 -0400

si-local-file:///var/storage/secattach/20260803/26853551.html

Supernus and Indivior agree to all-stock merger of equals

Mon, 03 Aug 2026 06:31:16 -0400

Supernus Pharmaceuticals (NASDAQ: SUPN) and Indivior Pharmaceuticals (NASDAQ: INDV) have entered into a definitive agreement to combine in a tax-free all-stock merger, the companies announced Aug. 3, 2026, according to a joint press release.

Under the terms of the deal, unanimously approved by both boards, Supernus stockholders will receive 1.5401 common shares of Indivior for each share they hold. Indivior stockholders will receive a one-time special cash dividend of $1.0 billion in aggregate immediately prior to closing. To fund the dividend, the companies have secured a $650 million term loan commitment from Citibank N.A., with the remainder drawn from existing cash.

Upon